Ucb SA
OTC:UCBJF
Intrinsic Value
UCB SA engages in the research and development biopharmaceuticals products. [ Read More ]
The intrinsic value of one UCBJF stock under the Base Case scenario is 98.48 USD. Compared to the current market price of 126.05 USD, Ucb SA is Overvalued by 22%.
Valuation Backtest
Ucb SA
Run backtest to discover the historical profit from buying and selling UCBJF stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ucb SA
Current Assets | 3.4B |
Cash & Short-Term Investments | 1.1B |
Receivables | 1.3B |
Other Current Assets | 1.1B |
Non-Current Assets | 12.1B |
Long-Term Investments | 210m |
PP&E | 1.6B |
Intangibles | 9.5B |
Other Non-Current Assets | 804m |
Current Liabilities | 2.6B |
Accounts Payable | 2.3B |
Other Current Liabilities | 303m |
Non-Current Liabilities | 3.9B |
Long-Term Debt | 3B |
Other Non-Current Liabilities | 952m |
Earnings Waterfall
Ucb SA
Revenue
|
5.3B
EUR
|
Cost of Revenue
|
-1.7B
EUR
|
Gross Profit
|
3.5B
EUR
|
Operating Expenses
|
-3B
EUR
|
Operating Income
|
514m
EUR
|
Other Expenses
|
-171m
EUR
|
Net Income
|
343m
EUR
|
Free Cash Flow Analysis
Ucb SA
What is Free Cash Flow?
UCBJF Profitability Score
Profitability Due Diligence
Ucb SA's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Ucb SA's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
UCBJF Solvency Score
Solvency Due Diligence
Ucb SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Ucb SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UCBJF Price Targets Summary
Ucb SA
According to Wall Street analysts, the average 1-year price target for UCBJF is 131.16 USD with a low forecast of 79.71 USD and a high forecast of 183.64 USD.
Shareholder Return
UCB Price
Ucb SA
Average Annual Return | 3.89% |
Standard Deviation of Annual Returns | 20.79% |
Max Drawdown | -33% |
Market Capitalization | 23B EUR |
Shares Outstanding | 189 776 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
UCB SA engages in the research and development biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 8,615 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Contact
IPO
Employees
Officers
The intrinsic value of one UCBJF stock under the Base Case scenario is 98.48 USD.
Compared to the current market price of 126.05 USD, Ucb SA is Overvalued by 22%.